Ocular toxicity of high-dose intravenous desferrioxamine.
Desferrioxamine was given intravenously, at higher doses than previously reported, to counter the effects of transfusion-induced iron overload in four patients with beta thalassaemia major. In two of them retinal abnormalities developed, presenting with night blindness and field defects, which improved on withdrawal of the drug.
D000293:Adolescent; D000328:Adult; D002386:Cataract / Q000139:chemically induced*; D002648:Child; D002675:Child, Preschool; D003623:Dark Adaptation / Q000187:drug effects; D003676:Deferoxamine / Q000008:administration & dosage / Q000009:adverse effects*; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007223:Infant; D007263:Infusions, Parenteral; D007501:Iron / Q000506:poisoning; D008297:Male; D010786:Photoreceptor Cells / Q000187:drug effects; D012607:Scotoma / Q000139:chemically induced; D013789:Thalassemia / Q000628:therapy; D065227:Transfusion Reaction; D014792:Visual Acuity / Q000187:drug effects*; D014794:Visual Fields / Q000187:drug effects
D007501:Iron; D003676:Deferoxamine